HULK STACK is the Helix Bio name for a combined research formulation containing CJC-1295 Without DAC 5mg and Ipamorelin 5mg in one lyophilised vial. The two peptides are discussed together because they are associated with different receptor systems involved in growth-hormone research. That does not mean they are identical, interchangeable or proven to deliver any particular clinical outcome.
Research-use notice: This article is for general laboratory education. Helix Bio products are supplied strictly for research purposes only and are not intended for human or veterinary use, consumption, diagnosis, treatment or any clinical application. Nothing here is dosing, administration, treatment or medical advice.
What is in HULK STACK?
The listed composition is a total of 10mg: 5mg of CJC-1295 Without DAC and 5mg of Ipamorelin. A combined vial is a formulation choice. It does not create a new molecular entity, and the total milligram figure should not be mistaken for evidence about potency, activity, safety or suitability.
The two components belong to related but distinct areas of peptide research:
- CJC-1295 Without DAC is a commonly used commercial label for a shorter-acting, modified growth-hormone-releasing factor fragment, often described as modified GRF(1-29). It is associated with the growth-hormone-releasing hormone receptor, abbreviated GHRHR.
- Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue. Early pharmacology described activity through a GHRP-like receptor, now generally discussed in relation to the ghrelin receptor or growth-hormone secretagogue receptor, abbreviated GHSR.
These receptor pathways can converge on growth-hormone secretion in experimental systems, but convergence does not make the compounds equivalent. Each has its own structure, receptor interaction, pharmacokinetic behaviour and evidence base.
Two peptides, two receptor pathways
Growth-hormone-releasing hormone is an endogenous hypothalamic signal. It acts at GHRH receptors on pituitary somatotroph cells and helps regulate growth-hormone synthesis and release. GHRH fragments and analogues are studied because changes to sequence or chemical design can alter stability, receptor activity and duration of exposure.
Growth-hormone secretagogues use a different receptor system. Ipamorelin was characterised as a selective growth-hormone secretagogue in preclinical research, while a later dose-escalation study in healthy male volunteers examined its pharmacokinetic and pharmacodynamic profile. That study reported a transient episode of growth-hormone release after intravenous infusion. It did not test the Helix Bio formulation, long-term outcomes or consumer use.
Older human studies involving GHRH together with other growth-hormone-releasing peptides found that the two classes could produce enhanced acute growth-hormone responses under certain experimental conditions. This provides a biological reason for studying the pathways together. It is not direct proof for CJC-1295 Without DAC plus Ipamorelin, and it cannot be converted into claims about body composition, recovery, performance, ageing or wellbeing.
Why “CJC-1295 Without DAC” needs careful wording
The name CJC-1295 originally refers to a long-acting GHRH analogue designed with a Drug Affinity Complex, or DAC. The DAC group enables the molecule to form an albumin bioconjugate, extending exposure compared with an unconjugated GHRH fragment. The published human CJC-1295 studies that are cited most often investigated this long-acting DAC form.
In the research-supply market, the phrase CJC-1295 Without DAC is commonly used for modified GRF(1-29): a related GHRH fragment analogue without the albumin-binding DAC group. The label is familiar, but it can blur an important scientific distinction. Evidence generated with long-acting CJC-1295 with DAC should not automatically be assigned to the no-DAC material.
| Research term | What it usually means | Interpretation caution |
|---|---|---|
| CJC-1295 with DAC | The albumin-binding, long-acting GHRH analogue described in the original CJC-1295 programme. | Its human PK/PD findings do not directly establish the behaviour of a no-DAC formulation. |
| CJC-1295 Without DAC | A common market label for modified GRF(1-29), without the albumin-binding DAC group. | The precise identity must come from the specification and analytical documentation, not the nickname alone. |
This distinction also affects how half-life claims should be handled. A multi-day half-life reported for the albumin-binding DAC molecule should not be copied onto the shorter-acting no-DAC material. The Helix Bio peptide glossary explains half-life and other common laboratory terms.
What published research says about CJC-1295
A 2005 preclinical paper described hGRF(1-29)-albumin bioconjugates and identified CJC-1295 as a long-lasting GHRH analogue. A 2006 randomised, placebo-controlled programme then investigated long-acting CJC-1295 in healthy adults. Researchers measured growth hormone, IGF-I and pharmacokinetic variables after single and repeated administration.
Those studies are useful for understanding the DAC design and the biology of sustained GHRH-receptor stimulation. They do not directly test CJC-1295 Without DAC, the 5mg component in HULK STACK, or the combined 5mg plus 5mg formulation. This is the central evidence boundary for any accurate article about the product.
Research on native or modified GRF(1-29) helps explain why short GHRH fragments are biologically relevant, but sequence changes, formulation and route can materially alter behaviour. Similarity of name or receptor target is not enough to make two preparations scientifically interchangeable.
What published research says about Ipamorelin
Ipamorelin was described in 1998 as a pentapeptide growth-hormone secretagogue. Much of the selectivity work was preclinical. It compared growth-hormone release with effects on other pituitary or adrenal hormones in experimental models; it should not be read as proof of broad human safety.
A 1999 human dose-escalation study involved eight healthy male volunteers at each of five intravenous infusion rates. Researchers measured Ipamorelin concentrations and growth-hormone responses, producing a pharmacokinetic-pharmacodynamic model. This established that human PK/PD investigation exists, but it was a small, controlled experimental study—not a test of a combined commercial vial or long-term clinical outcomes.
Ipamorelin was also investigated in a randomised proof-of-concept study involving postoperative ileus after bowel resection. That specialist intravenous hospital study addressed a gastrointestinal endpoint in surgical patients. It does not establish claims about muscle gain, fat loss, injury recovery, sleep, anti-ageing or athletic performance.
Has the exact HULK STACK formulation been clinically tested?
No direct clinical-outcome evidence has been identified for the exact Helix Bio HULK STACK formulation containing CJC-1295 Without DAC 5mg and Ipamorelin 5mg in one vial. Evidence about either component, a different GHRH analogue, a different secretagogue or an acute laboratory hormone response cannot substitute for formulation-specific evidence.
That distinction matters because combined-formulation research can require answers to additional questions:
- Are both components correctly identified in the same sample?
- Can the analytical method distinguish and quantify each component?
- Does one component affect the stability, recovery or measurement of the other?
- How does the chosen formulation behave under defined storage conditions?
- Are reported observations pharmacodynamic, analytical, preclinical or clinical?
Without direct evidence, the appropriate conclusion is not that a claimed outcome is true or false. It is that the outcome remains unestablished for the exact formulation.
Why hormone-response data are not the same as practical outcomes
A pharmacodynamic marker shows that a biological variable changed under the conditions of a study. It does not automatically demonstrate a meaningful improvement in health, physical performance or body composition. Moving from a short-term hormone measurement to a practical outcome requires suitable endpoints, adequate sample size, an appropriate comparator, sufficient follow-up and a design that actually tests the claimed use.
This is especially important for the growth-hormone and IGF-I axis. Responses can vary with age, sex, nutritional state, sleep, body composition, metabolic health, timing and other physiological factors. A response measured in healthy volunteers under controlled conditions cannot simply be generalised to a different population or setting.
The responsible conclusion
HULK STACK combines two research peptides associated with different receptor pathways. Related studies make the combination scientifically discussable, but they do not establish clinical benefits, safety or performance outcomes for the exact product.
Identity, purity and batch traceability still matter
A product name and nominal milligram amount are not analytical results. For a combined peptide formulation, documentation should identify the sample and batch, state which tests were performed and make clear whether each component was assessed. A chromatographic purity percentage is not the same as molecular identity or quantitative content.
Use the Helix Bio guide on how to read a peptide Certificate of Analysis to review sample identity, batch traceability, methods, results and report limits. The Certificates of Analysis page shows the current documentation status. A pending report is not a completed or passed test.
Storage can also influence peptide integrity. Read the label, batch-specific documents and the peptide storage and stability guide together. General storage advice cannot replace formulation-specific stability data.
Sport and anti-doping context
The World Anti-Doping Agency’s 2026 Prohibited List includes growth-hormone-releasing factors and analogues such as CJC-1295, as well as growth-hormone secretagogues and mimetics including Ipamorelin, within the peptide hormones and growth-factors category. Athletes and support personnel should treat this as a strict compliance issue and consult their governing anti-doping body rather than relying on product marketing or research-use labelling.
Frequently asked questions
What does HULK STACK contain?
The Helix Bio listing states CJC-1295 Without DAC 5mg and Ipamorelin 5mg, for a total nominal content of 10mg in one lyophilised research vial.
Are CJC-1295 Without DAC and Ipamorelin the same type of peptide?
No. CJC-1295 Without DAC is associated with a GHRH-receptor pathway, while Ipamorelin is a growth-hormone secretagogue associated with the GHS receptor. Their research contexts overlap, but their structures and receptor interactions differ.
Is CJC-1295 Without DAC the same as CJC-1295 with DAC?
No. The no-DAC name is commonly used for modified GRF(1-29), while the original CJC-1295 programme used an albumin-binding DAC design. Findings from one should not automatically be assigned to the other.
Does research on separate ingredients prove the combined formulation works?
No. Component-level or related-class evidence can explain scientific rationale, but it is not formulation-specific proof. Direct studies would be needed to establish outcomes for the exact combination.
Does HULK STACK have established muscle-building or fat-loss benefits?
No such clinical benefits are established for the exact Helix Bio formulation. Acute hormone-response research should not be converted into body-composition, recovery, performance or anti-ageing claims.
Is HULK STACK approved as a medicine?
Helix Bio supplies this product strictly as a laboratory research material, not as a medicine and not for human or veterinary use. Research-use wording does not itself establish regulatory approval, safety or suitability.
Sources and further reading
- Jette et al. Human hGRF(1-29)-albumin bioconjugates and identification of CJC-1295, Endocrinology, 2005.
- Teichman et al. CJC-1295 pharmacokinetic and pharmacodynamic research in healthy adults, Journal of Clinical Endocrinology & Metabolism, 2006.
- Raun et al. Ipamorelin, the first selective growth-hormone secretagogue, European Journal of Endocrinology, 1998.
- Gobburu et al. Pharmacokinetic-pharmacodynamic modelling of Ipamorelin in human volunteers, Pharmaceutical Research, 1999.
- Beck et al. Randomised proof-of-concept Ipamorelin study in postoperative ileus, International Journal of Colorectal Disease, 2014.
- Bowers et al. Human research on GHRP and GHRH co-administration, Journal of Clinical Endocrinology & Metabolism, 1990.
- World Anti-Doping Agency: 2026 Prohibited List.
For research purposes only — not for human consumption.
This article provides general educational information about peptide research and evidence interpretation. It does not provide dosing, administration, treatment or clinical-use guidance.
Last reviewed: 20 October 2026.